Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera, Inc. (NASDAQ: NTRA) has announced significant advancements in commercial coverage for its Signatera molecular residual disease test. Effective March 1, 2023, Blue Shield of California will cover Signatera for all solid tumor patients, marking the company's first pan-cancer policy. Additionally, as of January 1, 2023, Blue Cross and Blue Shield of Louisiana will provide coverage for colorectal and bladder cancer monitoring. This underscores the medical necessity and enhanced access to Signatera testing, which has been validated through approximately 40 peer-reviewed publications for its efficacy in detecting cancer recurrence earlier than traditional methods.
Natera, Inc. (NASDAQ: NTRA) reported a robust performance for Q4 2022, achieving total revenues of $217.3 million, a 25.6% increase from Q4 2021. For the full year 2022, revenues reached $820.2 million, marking a 31.1% growth. The company processed approximately 559,700 tests in Q4 2022, up by 27.6% year-over-year, and over 2 million tests for the year, a 31.6% rise. However, gross margins declined to 41.4% in Q4 2022 from 45.6% in Q4 2021 due to higher costs. Looking ahead, Natera expects 2023 revenues between $980 million and $1 billion and aims to reduce cash burn by approximately $150 million.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, is set to present at two upcoming investor conferences. The first is the Raymond James 44th Annual Institutional Investors Conference on March 7 at 2:50 p.m. ET in Orlando, FL. The second is the Cowen 43rd Annual Health Care Conference on March 8 at 11:10 a.m. ET in Boston, MA. Live webcasts will be available on the Natera investor relations website, with replays accessible shortly after each event. Natera focuses on personalized genetic testing in oncology, women's health, and organ health, supported by over 100 peer-reviewed publications.
Natera, Inc. (NASDAQ: NTRA) has appointed Ruth E. Williams-Brinkley to its board of directors, effective March 2, 2023. With over three decades of experience in the healthcare sector, she currently leads Kaiser Permanente Health Plan of the Mid-Atlantic States, overseeing operations for approximately 830,000 members. Williams-Brinkley's leadership is expected to enhance Natera's capabilities, particularly in oncology and women's health. CEO Steve Chapman expressed confidence in her contribution, highlighting her expertise as valuable for the company’s growth.
Natera, Inc. (NASDAQ: NTRA) will announce its fourth quarter and year-end results for 2022 on February 28, 2023, after market close. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial performance. Investors can access the conference through a live dial-in number or a webcast link. Natera specializes in cell-free DNA testing in fields like oncology and women's health, with a mission to enhance personalized genetic testing as a standard healthcare practice.
Natera, Inc. (NASDAQ: NTRA) has received confirmation from the Centers for Medicare & Medicaid Services (CMS) for coverage of its Signatera molecular residual disease test in patients with stage IIb or higher breast cancer. This coverage extends to all breast cancer subtypes, enhancing previous coverage for colorectal cancer and others. The decision is supported by the Exploratory Breast Lead Interval Study, showing Signatera's 89% sensitivity and 100% specificity for early relapse detection. This marks a significant milestone in precision oncology and patient care.
Natera, Inc. (NASDAQ: NTRA) has published a new paper in Pediatric Nephrology showcasing the clinical utility of its Renasight™ test for kidney disease diagnosis. The case study details a 16-year-old patient with sickle cell disease who was identified with autosomal dominant polycystic kidney disease (ADPKD) through genetic testing. This revelation emphasizes the importance of broad-panel genetic testing in managing patients with dual genetic conditions. Natera is conducting a prospective study, RenaCARE, across over 30 sites in the U.S. to further establish the test's clinical benefits.
Natera, Inc. (NASDAQ: NTRA) has announced new data on its personalized molecular residual disease (MRD) test, Signatera, set to be presented at the ASCO GI 2023 from January 19-21 in San Francisco. The presentations will showcase Signatera's effectiveness in assessing MRD across various gastrointestinal cancers, including colorectal and anal cancers. Notably, a study involving 14,425 patients suggests that MRD testing could commence as early as 2 weeks post-surgery, maintaining test sensitivity. This supports Signatera’s role in personalized cancer treatment. For further details, visit Natera’s website.
Natera, Inc. (NASDAQ: NTRA) has published a new study in Nature Medicine, highlighting the efficacy of the SignateraTM molecular residual disease (MRD) test for identifying patients with stage II-IV colorectal cancer at risk of recurrence. Data from the GALAXY arm of the CIRCULATE-Japan trial revealed that MRD-positive patients (18%) significantly benefited from adjuvant chemotherapy (ACT), while MRD-negative patients (82%) did not. The study also confirmed a pre-surgical detection rate of 95.9% for stage II-III patients, emphasizing the predictive power of Signatera in treatment decisions. This evidence builds on prior findings at ASCO GI 2022.
Natera, Inc. (NASDAQ: NTRA) announced it will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 9:45 a.m. PT (12:45 p.m. ET). Natera's management will deliver a presentation and host a Q&A session with investors. The presentation can be accessed via a live webcast on Natera's Investor Relations website, where it will also be archived for later viewing. Natera is a leader in cell-free DNA testing focused on oncology, women's health, and organ health, with a commitment to advancing personalized genetic testing.